Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 open label, dose escalation trial in healthy adult volunteers assessing safety and immunogenicity of two SARS CoV-2 virus DNA vaccine candidates: an RBD candidate and a T-cell candidate

Next Previous
Trial Profile

A phase 1/2 open label, dose escalation trial in healthy adult volunteers assessing safety and immunogenicity of two SARS CoV-2 virus DNA vaccine candidates: an RBD candidate and a T-cell candidate

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VB10 COV2 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 19 Jul 2021 New trial record
  • 12 Jul 2021 According to Vaccibody AS media release, the CTA (Clinical Trial Application) is expected to be submitted in Q3 2021 and initiation of this trial is planned for Q4 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top